ucpvax
Vaccineexperimental
Clinical trial activity
5 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2016 (NCT02818426)
Timeline
Indications
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ucpvax
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05528952 | Phase 2 | Sep 27, 2022 | Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR), University of Franche-Comté |
| NCT04263051 | Phase 2 | Apr 1, 2020 | Bristol-Myers Squibb, Fondation ARC, University of Franche-Comté |
| NCT04280848 | Phase 1/Phase 2 (Phase 2) | Mar 31, 2020 | CHU Besançon, University of Franche-Comté |
| NCT03946358 | Phase 2 | Sep 30, 2019 | CHU Besançon, National Cancer Institute, France, Roche, University of Franche-Comté |
| NCT02818426 | Phase 1/Phase 2 (Phase 2) | May 1, 2016 | Invectys, University of Franche-Comté |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Franche-Comté | Academic/Hospital | 5 | 5 | 1 | 2016 |
| CHU Besançon | Academic/Hospital | 2 | 0 | 1 | 2019 |
| Bristol-Myers Squibb | For profit | 1 | 0 | 1 | 2020 |
| Fondation ARC | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR) | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Invectys | For profit | 1 | 0 | 1 | 2016 |
| National Cancer Institute, France | Government | 1 | 0 | 1 | 2019 |
| Roche | For profit | 1 | 0 | 1 | 2019 |
8 organizations
Page 1 / 1